| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Launched new corporate brand as AchieveRx, The Quit Company (Nasdaq: QUIT) |
| 01 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 1, 2026, Achieve Life Sciences, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed Benjamin Halladay as the Company’s Chief Financial Officer and “principal financial officer,” ef... |
| 14 Aug 2026 |
8-K: Other Events
Achieve Life Sciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent (the “Agent”), shares of the Comp... |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval |
| 06 Jul 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Achieve Life Sciences, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: |
| 02 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On May 29, 2026, the Board of Directors (the “Board”) of Achieve Life Sciences, Inc. (the “Company”) appointed Jeff Farrow and Reid Waldman, M.D. (together, the “Incoming Directors”), as directors, effective as of such date. Mr. Marrow h... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Closed Private Placement of Up to $354 Million, Including $180 Million Upfront and $174 Million in Milestone-Driven Warrants |
| 16 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of April 15, 2026, by and among Achieve Life Sciences, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreemen... |
| 24 Mar 2026 |
8-K: Results of Operations and Financial Condition
Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Vaping Cessation |
| 07 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 11, 2025, Achieve Life Sciences, Inc. (the “Company”) previously announced that Dr. Cindy Jacobs had informed the Company’s board of directors that she had elected to resign from her role as the Company’s Chief Medical Offic... |
| 11 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 5, 2025, Dr. Cindy Jacobs informed the board of directors (the “Board”) of Achieve Life Sciences, Inc. (the “Company”), that she has elected to resign from her role as the Company’s Chief Medical Officer and President, effec... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Conference Call Scheduled for 8:30 AM EDT Today, August 7, 2025 |
| 27 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
The undersigned, Achieve Life Sciences, Inc., a company incorporated under the laws of Delaware (collectively with its subsidiaries, including, without limitation, all entities disclosed or described in the Registration Statement as bein... |
| 06 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
The Annual Meeting of Stockholders of Achieve Life Sciences, Inc. (the “Company”) was held on June 4, 2025. The following is a brief description of each matter voted upon and the certified voting results. |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition
Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 |
| 11 Mar 2025 |
8-K: Results of Operations and Financial Condition
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program |
| 10 Feb 2025 |
8-K: Other Events
Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial |
| 10 Jan 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On January 6, 2025, Dr. Vaughn Himes informed the board of directors (the “Board”) of Achieve Life Sciences, Inc. (the “Company”), that he has elected to resign from his position as a member of the Board, effective immediately. Dr. Himes... |
| 09 Dec 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
On December 9, 2024, Achieve Life Sciences, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed Mark K. Oki as the Company’s Chief Financial Officer and “principal financial officer,” effecti... |
Loading...